Squarepoint
CLYM icon

Squarepoint’s Climb Bio CLYM Stock Holding History

Squarepoint’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338K Sell
25,956
-17,018
-40% -$176K ﹤0.01% 3719
2026
Q1 		$294K Buy
+42,974
New +$248K ﹤0.01% 3730
2025
Q4 		– Sell
-17,699
Closed -$35.6K – 5034
2025
Q3 		$35.6K Sell
17,699
-1,941
-10% -$3.6K ﹤0.01% 4257
2025
Q2 		$24.4K Buy
+19,640
New +$24.4K ﹤0.01% 4377
2025
Q1 		– Sell
-30,845
Closed -$55.5K – 5594
2024
Q4 		$55.5K Buy
+30,845
New +$112K ﹤0.01% 4823

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's CLYM Position: Q2 2026 in Review

Squarepoint reduced its Climb Bio (CLYM) stake by 40% in Q2 2026, selling an estimated $176K and leaving 25,956 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #3719.

Squarepoint first reported a position in CLYM in Q4 2024 and has held it in 5 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Squarepoint held 25,956 shares of Climb Bio worth $338K as of Q2 2026.
  • Squarepoint sold 17,018 Climb Bio shares in Q2 2026, an estimated $176K.
  • Climb Bio made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3719 holding.
  • Squarepoint first reported a position in Climb Bio in Q4 2024 and has held it in 5 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.